...
首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Pharmacologic options available to treat symptomatic intradialytic hypotension.
【24h】

Pharmacologic options available to treat symptomatic intradialytic hypotension.

机译:可用于治疗有症状的透析内低血压的药理学选择。

获取原文
获取原文并翻译 | 示例
           

摘要

Treatment of symptomatic intradialytic hypotension (IDH) is a difficult task for the practicing nephrologist. Minimizing patient factors that precipitate IDH as well as dialysis procedure-related components that lower blood pressure are the initial approaches to this problem. However, despite these maneuvers, hypotension often persists in a group of high-risk patients. Pharmacologic interventions are often used to reduce IDH. Unfortunately, many of the available therapies are marginally effective and/or poorly tolerated. A few therapies appear to be efficacious and well tolerated-carnitine, sertraline, and midodrine. This article reviews the various pharmacologic therapies used for IDH and makes recommendations for treatment of this difficult problem.
机译:对有症状的透析内低血压(IDH)的治疗对于执业的肾脏科医生来说是一项艰巨的任务。最小化沉淀IDH的患者因素以及与降低血压的透析程序相关的组件是解决此问题的最初方法。然而,尽管采取了这些措施,但一组高危患者通常仍会出现低血压。药物干预通常用于减少IDH。不幸的是,许多可用的疗法勉强有效和/或耐受性差。一些疗法似乎是有效且耐受性良好的肉碱,舍曲林和米多君。本文回顾了用于IDH的各种药物疗法,并提出了治疗该难题的建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号